About Us

Key Figures

Current studies

New students / year

Inclusions / year

Visits per year

The distribution of fields of study at the CIC reflects a high degree of diversification, with major initiatives in neurology and neuropsychiatry, reflecting the center’s commitment to advanced and specialized research.

Here is an example of studies that have been completed or are currently underway at the CIC Neurosciences

NS PARK

Abnormal movements

Cohort of the French Clinical Research Network on Parkinson's Disease

ICEBERG

Abnormal movements

A non-pharmaceutical cohort study to identify factors associated with the progression from
to Parkinson’s disease and to validate biomarkers for monitoring dopaminergic
and non-dopaminergic lesions.

LTS17043

Inflammatory diseases of the central nervous system

A Phase 3 interventional study to evaluate the long-
-term safety and tolerability of tolebrutinib in patients with relapsing multiple sclerosis, primary progressive multiple sclerosis, or non-relapsing secondary progressive multiple sclerosis.

ACUITY

Inflammatory diseases of the central nervous system

A randomized, double-blind study to evaluate the safety and tolerability of OCS-05 compared with placebo in patients with unilateral acute optic neuritis (AON).

CART T CELL

Inflammatory diseases of the central nervous system

A Phase 1, multicenter, single-arm study evaluating the safety and tolerability of CC-97540 (BMS-986353), a CD19-targeting NEX-T CAR T cell, in patients with relapsing forms of multiple sclerosis (MS-R) or progressive forms of multiple sclerosis (MS-P)

ATLAS

Amyotrophic Lateral Sclerosis (ALS) or Charcot's disease

A Phase III, randomized, placebo-controlled study with an initial observational period to assess the preclinical natural history of the disease and an open-label extension period evaluating BIIB067 in presymptomatic adults with a confirmed mutation in the superoxide dismutase 1 gene

IASO

Amyotrophic Lateral Sclerosis (ALS) or Charcot's disease

Safety and tolerability assessment, including analysis of the gut microbiota, of an oral microbiotherapy for amyotrophic lateral sclerosis; an open-label Phase Ib pilot study

CNIO752B12201

Dementias

A randomized, double-blind (participant- and investigator-blind), placebo-
, controlled study to evaluate the ability of a single dose of NIO752, administered intrathecally, to reduce the concentration of total tau protein in the cerebrospinal fluid of patients with Alzheimer’s disease

RESSTORE 1b

Neurovascular

Regenerative cell therapy following a stroke

COMPASS

Psychiatry

A Phase III, multicenter, randomized, double-blind, controlled study to evaluate the efficacy, safety, and tolerability of two initial doses of COMP360 in patients with treatment-resistant depression (TRD)

ION717-CS2

Prion diseases

A Phase I/IIa study to evaluate the safety, tolerability, pharmacokinetic profile, and pharmacodynamics of ION717 administered intrathecally in a patient subgroup with prion diseas

Key Figures

Current studies

New students / year

Inclusions / year

Visits per year

The distribution of fields of study at the CIC reflects a high degree of diversification, with major initiatives in neurology and neuropsychiatry, reflecting the center’s commitment to advanced and specialized research.

Here is an example of studies that have been completed or are currently underway at the CIC Neurosciences

NS PARK

Abnormal movements

Cohort of the French Clinical Research Network on Parkinson's Disease

ICEBERG

Abnormal movements

A non-pharmaceutical cohort study to identify factors associated with the progression from
to Parkinson’s disease and to validate biomarkers for monitoring dopaminergic
and non-dopaminergic lesions.

LTS17043

Inflammatory diseases of the central nervous system

A Phase 3 interventional study to evaluate the long-
-term safety and tolerability of tolebrutinib in patients with relapsing multiple sclerosis, primary progressive multiple sclerosis, or non-relapsing secondary progressive multiple sclerosis.

ACUITY

Inflammatory diseases of the central nervous system

A randomized, double-blind study to evaluate the safety and tolerability of OCS-05 compared with placebo in patients with unilateral acute optic neuritis (AON).

CART T CELL

Inflammatory diseases of the central nervous system

A Phase 1, multicenter, single-arm study evaluating the safety and tolerability of CC-97540 (BMS-986353), a CD19-targeting NEX-T CAR T cell, in patients with relapsing forms of multiple sclerosis (MS-R) or progressive forms of multiple sclerosis (MS-P)

ATLAS

Amyotrophic Lateral Sclerosis (ALS) or Charcot's disease

A Phase III, randomized, placebo-controlled study with an initial observational period to assess the preclinical natural history of the disease and an open-label extension period evaluating BIIB067 in presymptomatic adults with a confirmed mutation in the superoxide dismutase 1 gene

IASO

Amyotrophic Lateral Sclerosis (ALS) or Charcot's disease

Safety and tolerability assessment, including analysis of the gut microbiota, of an oral microbiotherapy for amyotrophic lateral sclerosis; an open-label Phase Ib pilot study

CNIO752B12201

Dementias

A randomized, double-blind (participant- and investigator-blind), placebo-
, controlled study to evaluate the ability of a single dose of NIO752, administered intrathecally, to reduce the concentration of total tau protein in the cerebrospinal fluid of patients with Alzheimer’s disease

RESSTORE 1b

Neurovascular

Regenerative cell therapy following a stroke

COMPASS

Psychiatry

A Phase III, multicenter, randomized, double-blind, controlled study to evaluate the efficacy, safety, and tolerability of two initial doses of COMP360 in patients with treatment-resistant depression (TRD)

ION717-CS2

Prion diseases

A Phase I/IIa study to evaluate the safety, tolerability, pharmacokinetic profile, and pharmacodynamics of ION717 administered intrathecally in a patient subgroup with prion diseas

CIC Activity Report

Learn more ...

CIC Activity Report

Learn more ...

The Steering Committee

Medical Coordinator

C. Louapre

Medical Director

G. Mangone

Pharmacologist

L. L. Mariani

ARC Coordinator

S. Taieb-Tamacha

Administrative and Financial Manager

N. Roz

Healthcare Manager

Multidisciplinary team

The CIC relies on a multidisciplinary team whose diverse expertise ensures the excellence of its clinical research projects.

This synergy of expertise ensures comprehensive and innovative support for every project.

NEUROLOGIST

Responsible for overseeing the protocol. He or she obtains informed consent from participants and provides medical follow-up throughout the study.

NEUROPSYCHOLOGIST

Conducts neuropsychological testing when required by the protocol.

NURSE

Coordinates the logistical, administrative, and material aspects of medical examinations and provides medical care

CARE ASSISTANT

They are responsible for welcoming, registering, and settling in participants. They also maintain the facilities and equipment.

CLINICAL RESEARCH ASSISTANT

Coordinates the logistical, administrative, and material aspects of research projects

LABORATORY TECHNICIAN

Responsible for preparing and shipping biological samples.

ADMINISTRATIVE STAFF

Handles medical administrative tasks and arranges for reimbursement of transportation costs and compensation, if applicable.

Why not you?

Please feel free to contact us directly via the contact section

The Steering Committee

Medical Coordinator

C. Louapre

Medical Director

G. Mangone

Pharmacologist

L. L. Mariani

ARC Coordinator

S. Taieb-Tamacha

Administrative and Financial Manager

N. Roz

Healthcare Manager

Multidisciplinary team

The CIC relies on a multidisciplinary team whose diverse expertise ensures the excellence of its clinical research projects.

This synergy of expertise ensures comprehensive and innovative support for every project.

NEUROLOGIST

Responsible for overseeing the protocol. He or she obtains informed consent from participants and provides medical follow-up throughout the study.

NEUROPSYCHOLOGIST

Conducts neuropsychological testing when required by the protocol.

NURSE

Coordinates the logistical, administrative, and material aspects of medical examinations and provides medical care

CARE ASSISTANT

They are responsible for welcoming, registering, and settling in participants. They also maintain the facilities and equipment.

CLINICAL RESEARCH ASSISTANT

Coordinates the logistical, administrative, and material aspects of research projects

LABORATORY TECHNICIAN

Responsible for preparing and shipping biological samples.

ADMINISTRATIVE STAFF

Handles medical administrative tasks and arranges for reimbursement of transportation costs and compensation, if applicable.

Why not you?

Please feel free to contact us directly via the contact section

Let's work together!